STAT+: Rick Doblin, ‘unleashed,’ blasts FDA over Lykos drug rejection and turns to global push for MDMA therapy
STAT
AUGUST 17, 2024
It’s been a hard week for the psychedelics pioneer Rick Doblin. First, the Food and Drug Administration declined to approve the MDMA-assisted therapy for post-traumatic stress disorder developed by Lykos Therapeutics, a company that he founded. The next day, the journal Psychopharmacology retracted three studies on the treatment, in which many authors were associated with Lykos or the nonprofit Doblin founded, the Multidisciplinary Association for Psychedelic Studies (MAPS).
Let's personalize your content